WO2017087679A3 - Bacterial proteases targeting the nf-kb transcription factor family - Google Patents

Bacterial proteases targeting the nf-kb transcription factor family Download PDF

Info

Publication number
WO2017087679A3
WO2017087679A3 PCT/US2016/062541 US2016062541W WO2017087679A3 WO 2017087679 A3 WO2017087679 A3 WO 2017087679A3 US 2016062541 W US2016062541 W US 2016062541W WO 2017087679 A3 WO2017087679 A3 WO 2017087679A3
Authority
WO
WIPO (PCT)
Prior art keywords
transcription factor
factor family
bacterial proteases
goga
gtga
Prior art date
Application number
PCT/US2016/062541
Other languages
French (fr)
Other versions
WO2017087679A2 (en
Inventor
Jorge E. Galan
Hui Sun
Original Assignee
Yale University
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Yale University filed Critical Yale University
Publication of WO2017087679A2 publication Critical patent/WO2017087679A2/en
Publication of WO2017087679A3 publication Critical patent/WO2017087679A3/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/164—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Immunology (AREA)
  • Medicinal Chemistry (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Chemical & Material Sciences (AREA)
  • Epidemiology (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)

Abstract

The present invention provides compositions and methods for treating or preventing a disease or disorder associated with increased NF-κΒ signaling. In certain aspects, the invention may be used treating cancer or inflammatory diseases. In one aspect, the invention is an agent which cleaves the NF-κΒ transcription factors RelA, RelB, cRel or a combination thereof. In another aspect, PipA, GtgA or GogA proteins or nucleic acids which encode PipA, GtgA or GogA inhibit NF-κΒ signaling.
PCT/US2016/062541 2015-11-17 2016-11-17 Bacterial proteases targeting the nf-kb transcription factor family WO2017087679A2 (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201562256468P 2015-11-17 2015-11-17
US62/256,468 2015-11-17

Publications (2)

Publication Number Publication Date
WO2017087679A2 WO2017087679A2 (en) 2017-05-26
WO2017087679A3 true WO2017087679A3 (en) 2017-07-20

Family

ID=58717841

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/US2016/062541 WO2017087679A2 (en) 2015-11-17 2016-11-17 Bacterial proteases targeting the nf-kb transcription factor family

Country Status (1)

Country Link
WO (1) WO2017087679A2 (en)

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2001011023A1 (en) * 1999-08-04 2001-02-15 Johnson & Johnson Research Pty Ltd Treatment of inflammatory or malignant disease using dnazymes
US8722613B2 (en) * 2003-08-29 2014-05-13 The Johns Hopkins University Methods and compositions for inhibition of nuclear factor kappaB

Patent Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2001011023A1 (en) * 1999-08-04 2001-02-15 Johnson & Johnson Research Pty Ltd Treatment of inflammatory or malignant disease using dnazymes
US8722613B2 (en) * 2003-08-29 2014-05-13 The Johns Hopkins University Methods and compositions for inhibition of nuclear factor kappaB

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
DATABASE NCBI 24 May 2013 (2013-05-24), "Virulence Protein [Salmonella enterica", XP055401181, Database accession no. WP_000938191 *

Also Published As

Publication number Publication date
WO2017087679A2 (en) 2017-05-26

Similar Documents

Publication Publication Date Title
ZA202004730B (en) Anti-claudin 18.2 antibodies and uses thereof
PH12019500596A1 (en) Recombinant binding proteins and their use
AU2016240220B2 (en) Designed ankyrin repeat domains with binding specificity for serum albumin
WO2018229236A3 (en) Compositions comprising bacterial strains
EP4253412A3 (en) Inhibition of cytokine-induced sh2 protein in nk cells
SG10201907660YA (en) Use of short chain fatty acids in cancer prevention
WO2020123300A3 (en) Kras variant mrna molecules
WO2016168592A3 (en) Compositions for modulating c9orf72 expression
WO2017177179A9 (en) Compositions and methods for treating cancer, inflammatory diseases and autoimmune diseases
MA41291A (en) PYRROLOTRIAZINONE AND IMIDAZOTRIAZINONE DERIVATIVES AS UBIQUE-SPECIFIC PROTEASE INHIBITORS No. 7 (USP7) FOR THE TREATMENT OF CANCER
MX2019015311A (en) Cannabidiolic acid esters compositions and uses thereof.
WO2017112528A3 (en) Interleukin-15 compositions and uses thereof
MX2018016057A (en) Compositions and methods for treating cardiovascular disease.
MX2022015248A (en) Methods of treating inflammatory diseases.
BR112015023207A8 (en) cynin compositions and methods for the prevention and treatment of disorders associated with c1 esterase inhibitor deficiency.
MX2023008211A (en) Compositions and methods for decreasing tau expression.
MX2017015922A (en) Biomarkers associated with lsd1 inhibitors and uses thereof.
EA201991455A1 (en) COMPOSITIONS AND METHODS FOR TREATING ALPHA-1-ANTITRIPSIN DEFICIENCY
WO2017151860A8 (en) Human kynureninase enzyme variants having improved pharmacological properties
WO2019173795A3 (en) Reduction of er-mam-localized app-c99 and methods of treating alzheimer's disease
CY1125031T1 (en) METHOD FOR GENE THERAPY USING AAV-XBP1S/GFP VIRUS AND USE THEREOF IN THE PREVENTION AND TREATMENT OF AMYOTROPHIC LATERAL SCLEROSIS
BR112016023519A2 (en) wnt / ß-catenin signaling inhibitor, pharmaceutical composition and method of treating and / or preventing a pathology defined by vascular malformation
IT201700025666A1 (en) Composition for use in the treatment of hypercholesterolemia and in the prevention of cardiovascular diseases.
BR112018072664A2 (en) compositions and methods for treating eye inflammation and infection
WO2017087679A3 (en) Bacterial proteases targeting the nf-kb transcription factor family

Legal Events

Date Code Title Description
121 Ep: the epo has been informed by wipo that ep was designated in this application

Ref document number: 16867141

Country of ref document: EP

Kind code of ref document: A2

NENP Non-entry into the national phase

Ref country code: DE

122 Ep: pct application non-entry in european phase

Ref document number: 16867141

Country of ref document: EP

Kind code of ref document: A2